搜索范围
T6654
应用筛选条件
关键词:'T6654'
显示 1-30 共 102 条结果 关于 "T6654" 范围 论文
Michael Levine et al.
The American journal of emergency medicine, 32(1), 71-74 (2013-10-15)
Clopidogrel is an adenosine diphosphate receptor antagonist. The risk of intracranial hemorrhage following minor head trauma in patients with pre-injury use of clopidogrel has not been fully determined. This case-controlled study examined the effects of pre-injury use of clopidogrel in
Antiplatelet therapy and anticoagulants - authors' reply.
Willem J M Dewilde et al.
Lancet (London, England), 382(9886), 25-25 (2013-07-09)
Bellal Joseph et al.
The American surgeon, 80(1), 43-47 (2014-01-10)
Anticoagulation agents are proven risk factors for intracranial hemorrhage (ICH) in traumatic brain injury (TBI). The aim of our study is to describe the epidemiology of prehospital coumadin, aspirin, and Plavix (CAP) patients with ICH and evaluate the use of
Ask the doctors. I recently had a drug-eluting stent placed in one of my coronary arteries after an episode of severe chest pain. My doctor told me I had to take Plavix every day. Now I feel perfectly fine-except for my right hip. I need a hip replacement, but my orthopedist wants to wait until I'm off Plavix before operating. How long is long enough to be on this drug?
Thomas Lee et al.
Harvard heart letter : from Harvard Medical School, 23(6), 2-2 (2013-07-19)
[What kind of antiplatelet treatment in acute coronary syndrome?--Intensive antiplatelet treatment only for patients with invasive strategy].
Thomas Meinertz
Deutsche medizinische Wochenschrift (1946), 138(45), 2288-2288 (2013-10-29)
Lesly A Pearce et al.
The Lancet. Neurology, 13(12), 1177-1185 (2014-12-03)
The primary outcome results for the SPS3 trial suggested that a lower systolic target blood pressure (<130 mm Hg) might be beneficial for reducing the risk of recurrent stroke compared with a higher target (130-149 mm Hg), but that the
Hrvoje Gasparovic et al.
The American journal of cardiology, 113(10), 1660-1667 (2014-03-29)
Coronary artery bypass grafting is pivotal in the contemporary management of complex coronary artery disease. Interpatient variability to antiplatelet agents, however, harbors the potential to compromise the revascularization benefit by increasing the incidence of adverse events. This study was designed
The chronovariability of platelet reactivity: a hurdle in the road to personalized antiplatelet therapy?
Ori Ben-Yehuda
Journal of the American College of Cardiology, 64(4), 369-371 (2014-07-26)
Yongjun Wang et al.
The New England journal of medicine, 369(1), 11-19 (2013-06-28)
Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than aspirin alone. In a randomized, double-blind, placebo-controlled trial
Stephen D Wiviott et al.
Lancet (London, England), 382(9892), 605-613 (2013-08-21)
Treatment with prasugrel and aspirin improves outcomes compared with clopidogrel and aspirin for patients with acute coronary syndrome who have had angiography and percutaneous coronary intervention; however, no clear benefit has been shown for patients managed first with drugs only.
ACP Journal Club. Adding clopidogrel to aspirin after TIA or minor ischemic stroke reduced stroke without increasing bleeding.
Michael D Hill
Annals of internal medicine, 159(8), JC5-JC5 (2013-10-16)
Laurent Feldman et al.
American heart journal, 168(6), 940-947 (2014-12-03)
Previous studies, which compared the prevalence of high on-clopidogrel platelet reactivity (HCPR) in type 2 diabetes mellitus (T2DM) versus non-T2DM and obese versus nonobese patients provided conflicting results. We compared the prevalence of HCPR in patients with T2DM, metabolic syndrome
Morten Lamberts et al.
Circulation, 129(15), 1577-1585 (2014-01-29)
The optimal long-term antithrombotic treatment of patients with coexisting atrial fibrillation and stable coronary artery disease is unresolved, and commonly, a single antiplatelet agent is added to oral anticoagulation. We investigated the effectiveness and safety of adding antiplatelet therapy to
Michelle T Harrison et al.
Thorax, 69(7), 609-615 (2014-04-20)
Evidence suggests that platelets play a significant role in inflammation in addition to their role in thrombosis. Systemic inflammation is linked to poor short and long term outcomes in COPD. Increased platelet activation has been reported in acute exacerbations of
Deborah B Diercks et al.
The American journal of emergency medicine, 31(7), 1005-1011 (2013-05-25)
American Heart Association/American College of Cardiology guidelines recommend that patients with definite unstable angina or non-ST-segment elevation myocardial infarction (NSTEMI) receive dual antiplatelet therapy on presentation to the hospital when undergoing early invasive management or "as soon as possible" after
Brad S Karon et al.
Clinical chemistry, 60(12), 1524-1531 (2014-10-05)
Anticoagulation protocols used during mechanical circulatory support call for titration of antiplatelet agents. We compared the precision and reliability of 5 platelet function tests in healthy volunteers and donors on daily antiplatelet therapy to distinguish their efficacy for titrating antiplatelet
The consult guys--balancing the medication portfolio 5 years after a heart attack.
Geno J Merli et al.
Annals of internal medicine, 161(12), CG12-CG12 (2014-12-17)
David L Wessel et al.
The New England journal of medicine, 368(25), 2377-2384 (2013-06-21)
Infants with cyanotic congenital heart disease palliated with placement of a systemic-to-pulmonary-artery shunt are at risk for shunt thrombosis and death. We investigated whether the addition of clopidogrel to conventional therapy reduces mortality from any cause and morbidity related to
Hidden implications: potential antiplatelet effects of adjuvant anaesthetic agents.
R A Callender et al.
Anaesthesia and intensive care, 41(4), 550-551 (2013-07-03)
Soraya Mezouar et al.
International journal of cancer, 136(2), 462-475 (2014-06-04)
Venous thromboembolism constitutes one of the main causes of death during the progression of a cancer. We previously demonstrated that tissue factor (TF)-bearing cancer cell-derived microparticles accumulate at the site of injury in mice developing a pancreatic cancer. The presence
Dual antiplatelet therapy after drug-eluting stents--how long to treat?
Antonio Colombo et al.
The New England journal of medicine, 371(23), 2225-2226 (2014-11-18)
Pierluigi Tricoci et al.
American heart journal, 168(6), 869-877 (2014-12-03)
Protease-activated receptor 1 antagonism with vorapaxar represents a novel strategy for platelet inhibition. In TRACER, vorapaxar was compared with placebo plus standard of care among 12,944 patients with non-ST-segment elevation acute coronary syndromes. We anticipated that most patients would have
Mathieu Pankert et al.
The American journal of cardiology, 113(1), 54-59 (2013-11-05)
This study aimed to analyze the impact of body mass index (BMI) and the metabolic syndrome (MS) on responses to clopidogrel or prasugrel and bleeding risk after acute coronary syndrome. The study included 1,542 consecutive patients who underwent coronary stenting
Aortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura.
Giulio Cavalli et al.
British journal of haematology, 166(4), 470-470 (2014-06-10)
S M Yvonne Zuurbier et al.
Nederlands tijdschrift voor geneeskunde, 157(25), A5836-A5836 (2013-06-20)
In patients with TIA or stroke of arterial origin various antiplatelet agents, or combinations of these, have been found to be effective to reduce the risk of new vascular complications. International guidelines currently recommend three treatment strategies with antiplatelet agents
Julie A Johnson et al.
Pharmacological reviews, 65(3), 987-1009 (2013-05-21)
The past decade has seen tremendous advances in our understanding of the genetic factors influencing response to a variety of drugs, including those targeted at treatment of cardiovascular diseases. In the case of clopidogrel, warfarin, and statins, the literature has
Ivanka Curkovic et al.
Praxis, 102(20), 1243-1250 (2013-10-04)
The most common risks related to platelet inhibitor therapy are bleeding, drug-drug interactions and therapeutic failure. The new substances prasugrel and ticagrelor are more potent platelet inhibitiors than clopidogrel. This reduces the incidence of ischemic events, but also potentially increases
Jolanta M Siller-Matula et al.
Clinical science (London, England : 1979), 128(2), 121-130 (2014-08-16)
This was a prospective study comparing two groups: personalized and non-personalized treatment with P2Y12 receptor blockers during a 12-month follow-up. We aimed to investigate whether personalized antiplatelet treatment in patients with high on-treatment platelet reactivity (HTPR) improves clinical outcome. Platelet
Dimitrios Alexopoulos et al.
American heart journal, 167(1), 68-76 (2013-12-18)
P2Y12 inhibitor switching has appeared in clinical practice as a consequence of prasugrel and ticagrelor availability, apart from clopidogrel, for use in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). In the context of the GReek AntiPlatelet
Nohra Chalouhi et al.
Stroke, 45(1), 54-58 (2013-11-21)
Flow diverters are currently indicated for treatment of large and complex intracranial aneurysms. The purpose of this study was to determine whether the indications of flow diversion can be safely extended to unruptured, small, saccular aneurysms (<10 mm) of the
1/4